Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
What I Wish I Knew Before Investing In Dividend Stocks
01:09pm, Tuesday, 14'th Jan 2025
Dividend investing has been very rewarding for me. However, I have learned a lot of lessons the hard way. I share some of the most important lessons I have learned in this article.
2 REITs That Make Sense To Own In 2025 And Beyond
07:45am, Tuesday, 14'th Jan 2025
Despite high-interest rates, REITs like Agree Realty and Realty Income offer attractive valuations and strong fundamentals, making them ideal for passive income investors. ADC boasts a 12% CAGR since
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
07:30am, Monday, 13'th Jan 2025
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GE
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
08:04pm, Sunday, 12'th Jan 2025
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration
Fire And Ice
09:00am, Sunday, 12'th Jan 2025
US equity markets tumbled this week while benchmark interest rates surged to the cusp of multi-decade highs after a critical slate of employment data showed surprisingly buoyant labor market trends. P
A Dozen Stocks I'm Buying As Rising Interest Rates Break The Market
08:05am, Saturday, 11'th Jan 2025
Interest rate peaks often cause short-term S&P 500 selloffs, especially for REITs. I retain hope that REITs may decouple from 10-year Treasury yields once rates stabilize. Baby Boomers' economic impac
Dividends On Repeat: 3 Monthly Payers You'll Love Forever
07:30am, Saturday, 11'th Jan 2025
Reliable monthly dividends are a game-changer for income investors, providing steady cash flow and financial peace of mind in any market. I share three top-notch monthly dividend payers that offer con
Agree Realty Announces Fourth Quarter 2024 Earnings Release Date and Conference Call Information
04:05pm, Tuesday, 07'th Jan 2025
ROYAL OAK, Mich. , Jan. 7, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it will release its fourth quarter and full year 2024 operating results after
Agree Realty Announces 2024 Investment Activity & 2025 Investment Outlook
04:05pm, Monday, 06'th Jan 2025
2025 Investment Guidance of $1.1 Billion to $1.3 Billion Balance Sheet Pre-Equitized with Liquidity of Over $2.0 Billion ROYAL OAK, Mich. , Jan. 6, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE:
Agree Realty: Still A Marginal Buy Case To Be Made Now
07:00am, Saturday, 04'th Jan 2025
A few months ago, Agree Realty upped its monthly dividend per share. The REIT delivered in the third quarter and looks positioned to keep generating solid AFFO per share growth. Agree Realty's credit
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Thursday, 02'nd Jan 2025
LAUSANNE, Switzerland , Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
3 High-Yield Asset Classes For Dividend Investors In 2025
08:29pm, Wednesday, 01'st Jan 2025
Traditional dividend valuation methods may not apply to all asset classes. Business Development Companies like Blue Owl Capital offer high yields through diverse debt investments, benefiting from high
LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
What Are The Top REITs For 2025?
08:25am, Monday, 30'th Dec 2024
REITs are offering a once-in-a-decade opportunity. They are heavily discounted and some enjoy strong catalysts in 2025. This could lead to significant upside. Here are some of my top picks.
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroen
